Physician profile
Sara-Ann E Fox
NPI 1194384826
$1,076.04
in general payments reported to CMS, 2019-2025
28 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.46 · 2023: $266 · 2024: $336 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $100.76 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $95.09 | 2023-2025 | |
| Glaxosmithkline, LLC. | $88.49 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $80.94 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.84 | 2023-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $77.81 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $76.38 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $53.67 | 2023-2025 | |
| Edwards Lifesciences Corporation | $33.11 | 2024 | Sapien 3 Ultra Resilia |
| Indivior INC. | $30.32 | 2025 | Sublocade |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.89 | 2023 | Lifevest |
| Neurocrine Biosciences, INC. | $27.63 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $26.33 | 2025 | Uptravi, Opsumit |
| Sk Life Science, INC. | $24.31 | 2023 | |
| Exact Sciences Corporation | $21.76 | 2023 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $21.38 | 2025 | |
| Lundbeck LLC | $21.28 | 2024 | Vyepti |
| Genentech USA, INC. | $20.20 | 2024 | Ocrevus |
| Mylan Specialty L.P. | $19.39 | 2024 | Yupelri |
| Inari Medical, INC. | $19.09 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Biotech, INC. | $18.61 | 2025 | |
| Merck Sharp & Dohme LLC | $17.98 | 2023 | Gardasil 9 |
| Inspire Medical Systems, INC. | $17.66 | 2025 | Inspire |
| Boston Scientific Corporation | $17.49 | 2024 | Watchman Flx |
| Teva Pharmaceuticals USA, INC. | $15.12 | 2024 | Austedo Xr |
| Abbott Laboratories | $14.65 | 2025 | Assurity |
| Amgen INC. | $14.53 | 2025 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $14.33 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara-Ann Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.